At India AI Impact Summit, Meta's chief AI officer Alexandr Wang said we are at the beginning of a true acceleration in technology and 2026 will mark an inflection point in many ways.

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25. 18.02.26 14:30 GlobeNewswire ...

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Senior researchers are leaving Elon Musk’s xAI as Anthropic discloses new safety findings and AI insiders issue unusually ...

Newly available videos and existing footage synchronized and assessed by The Times provide a frame-by-frame look at how an ICE officer ended up shooting and killing a motorist in Minneapolis. By The ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...